



Vivimed

Date: May 30, 2012

To

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

Dear Sir/Madam,

Subject : Outcome of Board Meeting

Ref. : Clause 41 of Listing Agreement

With reference to captioned subject and pursuant to Clause 41 of Listing Agreement entered into with the Stock Exchange, we are hereby submitting audited financial results for the financial results ended on March 31, 2012 approved by the Board of Directors at their meeting held on May 30, 2012. Board has also recommended

- (a) a final dividend of 3.5% on Compulsorily Convertible and Cumulative Preference Shares (CCPS's) on pro- rata basis for the financial year 2011-12.
- (b) a final dividend of Rs. 3/- per share (30%) on equity shares for the financial year 2011-12.

Highlights of Stand Alone Results are :

- YoY Sales up by Rs. 73 crores to Rs. 383 crores an increase of 24%
- YoY EBDITA up by Rs. 22 crores to Rs. 84 crores an increase of 35%
- YoY Profit after Tax up by Rs. 13 crores to Rs. 40 crores an increase of 46%

Highlights of Consolidated Results are :

- YoY Sales up by Rs. 252 crores to Rs. 668 crores an increase of 61%
- YoY EBDITA up by Rs. 47 crores to Rs. 133 crores an increase of 55%






Vivimed

- YoY Profit after Tax up by Rs. 14 crores to Rs. 63 crores an increase of 29%

This is for your information and record.

Thanking You,

For VIVIMED LABS LIMITED


SANTOSH VARALWAR

MANAGING DIRECTOR & CEO



Encl : As Above

PART - I

VIVIMED LABS LIMITED
STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31st, 2012

(INR in Lacs)

Sl. No.	Particulars	3 Months ended 31-03-2012	Preceding 3 Months ended 31-12-2011	Corresponding 3 Months ended 31-03-2011	Year to date figures for current period ended 31-03-2012	Previous Year ended 31-03-2011
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Income From Operations					
	(a) Net Sales / Income from Operations (Net of Excise Duty)	9,110.58	9,275.63	10,885.18	38,289.99	30,981.02
	(b) Other Operating Income	16.07	9.36	25.74	41.96	28.68
	Total Income From Operations (Net)	9,126.64	9,284.99	10,910.92	38,331.95	31,009.70
2	Expenses	7,248.56	7,583.06	9,786.19	30,944.43	25,949.72
	a. Cost of Raw Materials Consumed	4,752.53	5,581.04	6,998.74	22,930.02	19,884.48
	b. Purchase of Stock in Trade	-	-	-	-	-
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	671.40	(199.09)	16.79	(156.78)	(445.00)
	d. Employee Benefit Expenses	234.79	288.77	420.12	1,057.86	1,053.87
	e. Depreciation and Amortisation Expenses	456.17	209.81	236.64	1,055.10	503.09
	f. Other Expenditure	1,133.66	1,702.53	2,113.90	6,058.23	4,953.27
	Total Expenses	7,248.56	7,583.06	9,786.19	30,944.43	25,949.72
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	1,878.09	1,701.93	1,124.73	7,387.52	5,059.98
4	Other Income	-	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	1,878.09	1,701.93	1,124.73	7,387.52	5,059.98
6	Finance Costs	450.48	519.64	669.51	2,253.49	1,763.08
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	1,427.61	1,182.30	455.22	5,134.02	3,296.90
8	Exceptional items	-	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	1,427.61	1,182.30	455.22	5,134.02	3,296.90
10	Tax Expenses	350.99	236.55	(16.33)	1,092.57	520.58
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	1,076.61	945.75	471.55	4,041.46	2,776.32
12	Extraordinary Items (net of tax expenses Rs..... Lacs)	-	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	1,076.61	945.75	471.55	4,041.46	2,776.32
14	Share of Profit / (Loss) of associates *	-	-	-	-	-



15	Minority Interest *	-	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	1,076.61	945.75	471.55	4,041.46	2,776.32
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	13,933,942	13,933,942	10,164,016	13,933,942	10,164,016
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	25,672.32	-	-	25,672.32	-
19	annualised)					
	(a) Basic	7.73	6.79	4.64	29.00	27.32
	(b) Diluted	7.73	5.89	4.05	25.16	23.82

1. The above Standalone Unaudited Financial Results for the Quarter ended March 31, 2012 and Audited Financial Results for the Year Ended March 31, 2012 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on May 30, 2012.

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH VARAIWAR)

MANAGING DIRECTOR & CEO



Place : Hyderabad

Date : 30 / 05 / 2012

VIVIMED LABS LIMITED

Part II

Select Information for the Quarter and 12 Months Ended 31/03/2012

Sl. No.	Particulars	3 months ended 31/03/2012	Preceding 3 months ended 31/12/2011	Corresponding 3 months ended 31/03/2012 in the previous year	Previous Year ended 31/03/2011
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	Number of Shares	7,642,476	7,857,899	5,046,200	5,046,200
	Percentage of Shareholding	54.85%	56.39%	49.65%	49.65%
	Promoter and Promoter Group Shareholding				
	(a) Pledged / Encumbered				
	Number of Shares	1,052,455	1,052,455	1,052,455	1,052,455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	16.73%	17.32%	20.56%	20.56%
	Percentage of shares (as a % of the total share capital of the company)	7.55%	7.55%	10.35%	10.35%
	(b) Non -encumbered				
	Number of Shares	5,239,011	5,023,588	4,065,361	4,065,361
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	83.27%	82.68%	79.44%	79.44%
	Percentage of shares (as a % of the total share capital of the company)	39.60%	36.05%	40.00%	40.00%

Investors' Complaints :

Sl. No.	Particulars	3 months ended 31/03/2012
B		
	Pending at the beginning of the quarter	Nil
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the quarter	Nil



VIVIMED LABS LIMITED - STANDALONE
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING
OF THE LISTING AGREEMENT

(INR in Lacs)

Particulars	3 Months ended		12 Months ended	
	Unaudited		Audited	
	31-03-12	31-03-11	31-03-12	31-03-11
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)				
a. Speciality Chemicals Business	5,921.18	8,235.45	28,005.44	24,213.03
b. Pharma Business	2,534.07	2,649.72	10,483.29	6,767.99
Total	8,455.24	10,885.18	38,488.73	30,981.02
Less, Inter Segment Revenue	-	-	-	-
Net sales / Income from Operations	8,455.24	10,885.18	38,488.73	30,981.02
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment				
a. Speciality Chemicals Business	1,287.25	1,026.36	4,970.17	3,879.87
b. Pharma Business	590.84	274.29	2,417.35	1,180.10
Total	1,878.09	1,300.65	7,387.52	5,059.98
Less: 1. Interest	450.48	649.79	2,253.49	1,763.08
2. Other Un-allocable Expenditure	-	-	-	-
3. Un-allocable Income	-	-	-	-
Total Profit Before Tax	1,427.61	650.86	5,134.02	3,296.90
3. Capital Employed (Segment Assets - Segment Liabilities)				
a. Speciality Chemicals Business	30,449.24	34,957.12	30,449.24	34,957.12
b. Pharma Business	8,588.29	4,134.70	8,588.29	4,134.70
Total	39,037.53	39,091.82	39,037.53	39,091.82

Place : Hyderabad
Date : 30 / 05 / 2012



For VIVIMED LABS LIMITED

SANTOSH VARALWAR
MANAGING DIRECTOR & CEO

VIVIMED LABS LIMITED
Standlaone Statement of Assets and Liabilities
(INR in Lacs)

Sl. No.	Particulars	As at 31-03-2012	As at 31-03-2011
		Audited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders funds		
	(a) Share Capital	8,093.39	1,016.40
	(b) Reserves and Surplus	26,104.39	13,488.60
	(c) Money Received against Share Warrants	237.21	886.35
	Sub Total Shareholders Funds	34,434.99	15,391.35
2	Share application money pending allotment	-	-
3	Minority interest *		
4	Non-current liabilities		
	a) Long-term borrowings	13,359.80	4,962.44
	(b) Deferred tax liabilities (net)	1,731.35	1,568.92
	(c) Other long-term liabilities	473.63	991.42
	(d) Long-term provisions	180.90	164.91
	Sub-total - Non-current liabilities	15,745.69	7,687.68
5	Current liabilities		
	(a) Short-term borrowings	20,255.36	15,252.27
	(b) Trade payables	2,772.42	693.04
	(c) Other current liabilities	3,355.57	292.99
	(d) Short-term provisions	1,184.41	987.44
	Sub-total - Current liabilities	27,567.76	17,225.73
	TOTAL - EQUITY AND LIABILITIES	77,748.43	40,304.76
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	29,449.49	16,002.45
	(b) Capital Work In Progress	770.83	113.80
	(b) Goodwill on Consolidation*	-	-
	(c) Non Current Investment	8,716.93	339.87
	(d) Deferred Tax Assets (net)	-	-
	(e) Long Term Loans and advances	16,081.62	668.59
	(f) Other Non Current Assets	3,006.13	3,615.34
	Sub-total - Non-current assets	58,025.00	20,740.05
2	Current Assets		
	(a) Current investments	-	-
	(b) Inventories	7,388.21	6,670.55
	(c) Trade receivables	9,871.75	9,596.09
	(d) Cash and cash equivalents	1,940.55	863.18
	(e) Short-term loans and advances	499.97	2,434.07
	(f) Other current assets	22.95	0.83
	Sub-total - Current assets	19,723.43	19,564.71
	TOTAL - ASSETS	77,748.43	40,304.76



[Handwritten signature]

PART - I

VIVIMED LABS LIMITED
CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31st, 2012

(INR in Lacs)

Sl. No.	Particulars	3 Months ended 31-03-2012	Preceding 3 Months ended 31-12-2011	Corresponding 3 Months ended 31-03-2011	Year to date figures for current period ended 31-03-2012	Previous Year ended 31-03-2011
1	Income From Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
	(a) Net Sales / Income from Operations (Net of Excise Duty)	25,106.01	16,801.08	11,974.78	66,831.38	41,600.08
	(b) Other Operating Income	90.03	158.41	82.51	268.23	93.33
	Total Income From Operations (Net)	25,196.03	16,959.49	12,057.29	67,099.61	41,693.41
2	Expenses	21,824.00	14,328.27	10,243.00	56,480.55	34,107.57
	a. Cost of Raw Materials Consumed	11,525.30	8,958.74	5,922.71	35,573.68	24,155.79
	b. Purchase of Stock in Trade	-	-	-	-	-
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	202.11	(717.61)	288.70	(1,835.31)	(459.15)
	d. Employee Benefit Expenses	1,387.86	835.59	359.30	3,422.45	1,996.75
	e. Depreciation and Amortisation Expenses	1,345.77	689.95	356.89	2,678.94	914.58
	f. Other Expenditure (Any item exceeding 10 % of the total expenses relating to continuing operations to be shown separately)	7,362.96	4,561.61	3,315.40	16,640.79	7,499.60
	Total Expenses	21,824.00	14,328.27	10,243.00	56,480.55	34,107.57
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	3,372.04	2,631.21	1,814.29	10,619.06	7,585.84
4	Other Income	-	-	-	-	-
5	exceptional items (3 - 4)	3,372.04	2,631.21	1,814.29	10,619.06	7,585.84
6	Finance Costs	809.90	585.85	703.76	2,837.54	2,059.57
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	2,562.13	2,045.37	1,110.53	7,781.52	5,526.26
8	Exceptional items	-	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	2,562.13	2,045.37	1,110.53	7,781.52	5,526.26
10	Tax Expenses	332.54	440.07	(106.87)	1,467.84	643.09
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	2,229.59	1,605.30	1,217.40	6,313.68	4,883.17
12	Extraordinary Items (net of tax expenses Rs.....Lacs)	-	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	2,229.59	1,605.30	1,217.40	6,313.68	4,883.17
14	Share of Profit / (Loss) of associates *	-	-	-	-	-
15	Minority Interest *	-	-	-	-	-



16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	2,229.59	1,605.30	1,217.40	6,313.68	4,883.17
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)					
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	1,393.39	1,393.39	1,016.40	1,393.39	1,016.40
19	(not annualised)	-	-	-	-	-
	(a) Basic	16.00	11.52	11.98	45.31	48.04
	(b) Diluted	15.76	10.00	10.45	39.31	41.90

1. The above Consolidated Unaudited Financial Results for the Quarter ended March 31, 2012 and Audited Financial Results for the Year Ended March 31, 2012 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on May 30, 2012.

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sellen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Holdings Limited and its step down subsidiaries viz. (i) Vivimed Labs Europe Limited (ii) Vivimed Labs Mauritius Limited (iii) Vivimed Labs UK Limited, (iv) Vivimed Labs Spain, S.L. (v) Union Quimico Farmaceutica S.A.U., Spain, (vi) Uquifa Mexico S.A. de C.V. & (vii) Holiday International Limited, UK.

3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)

MANAGING DIRECTOR & CEO



Place : Hyderabad
Date : 30 / 05 / 2012

VIVIMED LABS LIMITED

Part II

Select Information for the Quarter and 12 Months Ended 31/03/2012

SL. No.	Particulars	3 months ended 31/03/2012	Preceding 3 months ended 31/12/2011	Corresponding 3 months ended 31/03/2012 in the previous year	Previous Year ended 31/03/2011
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	Number of Shares	7,642,476	7,857,899	5,046,200	5,046,200
	Percentage of Shareholding	54.85%	56.39%	49.65%	49.65%
	Promoter and Promoter Group Shareholding				
	(a) Pledged / Encumbered				
	Number of Shares	1,052,455	1,052,455	1,052,455	1,052,455
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	16.73%	17.32%	20.56%	20.56%
	(b) Non-encumbered	7.55%	7.55%	10.35%	10.35%
	Number of Shares	5,239,011	5,023,588	4,065,361	4,065,361
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	83.27%	82.68%	79.44%	79.44%
	Percentage of shares (as a % of the total share capital of the company)	39.60%	36.05%	40.00%	40.00%

Investors' Complaints :

SL. No.	Particulars	3 months ended 31/03/2012
B		
	Pending at the beginning of the quarter	Nil
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the quarter	Nil



VIVIMED LABS LIMITED - CONSOLIDATED
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE
LISTING AGREEMENT

(INR in lacs)

Particulars	3 Months ended		12 Months ended	
	Unaudited		Audited	
	31-03-12	31-03-11	31-03-12	31-03-11
1. Segment Revenue (Net Sales/ Income from each segment should be disclosed under this head)				
a. Speciality Chemicals Business	8,136.56	8,635.67	34,390.04	37,289.98
b. Pharma Business	17,059.47	3,339.13	34,544.88	9,972.41
Total	25,196.03	11,974.80	68,934.92	47,262.39
Less : Inter Segment Revenue	-	-	-	-
Net sales / Income from Operations	25,196.03	11,974.80	68,934.92	47,262.39
2. Segment Results (Profit)(+)/Loss(-) before tax and interest from each segment				
a. Speciality Chemicals Business	1,497.02	1,626.48	6,006.97	5,932.05
b. Pharma Business	1,875.02	363.61	4,612.10	1,653.72
Total	3,372.04	1,990.09	10,619.06	7,585.77
Less: 1. Interest	809.90	703.76	2,837.54	2,059.57
2. Other Un-allocable Expenditure net off	-	-	-	-
3. Un-allocable Income	-	-	-	-
Total Profit Before Tax	2,562.13	1,286.34	7,781.52	5,526.20
3. Capital Employed (Segment Assets - Segment Liabilities)				
a. Speciality Chemicals Business	44,192.64	47,838.70	44,192.64	47,838.70
b. Pharma Business	83,576.99	5,951.89	83,576.99	5,951.89
Total	127,769.63	53,790.58	127,769.63	53,790.58

For Vivimed Labs Limited

Place : Hyderabad
Date : 30 / 05 / 2012

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED
Consolidated Statement of Assets and Liabilities
(INR in Lacs)

Sl. No	Particulars	As at 31-03-2012	As at 31-03-2011
		Audited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders funds		
	(a) Share Capital	14,487.96	1,016.40
	(b) Reserves and Surplus	32,753.15	17,768.14
	(c) Money Received against Share Warrants	237.21	886.35
	Sub Total Shareholders Funds	47,478.31	19,670.89
2	Share application money pending allotment	-	-
3	Minority interest *		
4	Non-current liabilities		
	a) Long-term borrowings	33,732.53	13,189.86
	(b) Deferred tax liabilities (net)	1,344.05	1,465.21
	(c) Other long-term liabilities	175.52	-
	(d) Long-term provisions	180.90	164.91
	Sub-total - Non-current liabilities	35,433.00	14,819.97
5	Current liabilities		
	(a) Short-term borrowings	23,282.27	17,507.84
	(b) Trade payables	15,686.35	4,406.15
	(c) Other current liabilities	4,719.17	468.14
	(d) Short-term provisions	3,321.15	1,866.13
	Sub-total - Current liabilities	47,008.95	24,248.26
	TOTAL - EQUITY AND LIABILITIES	129,920.26	58,739.13
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	54,119.27	17,973.30
	(b) Capital Work In Progress	836.81	172.50
	(b) Goodwill on Consolidation*	5,415.17	8,455.53
	(c) Non Current Investment	69.80	-
	(d) Deferred Tax Assets (net)	-	-
	(e) Long Term Loans and advances	13,458.49	5,055.36
	(f) Other Non Current Assets	4,765.49	669.54
	Sub-total - Non-current assets	78,665.04	32,326.23
2	Current Assets		
	(a) Current investments	-	-
	(b) Inventories	24,787.74	8,447.50
	(c) Trade receivables	22,160.78	12,755.53
	(d) Cash and cash equivalents	3,633.68	1,109.60
	(e) Short-term loans and advances	650.07	4,099.46
	(f) Other current assets	22.95	0.80
	Sub-total - Current assets	51,255.22	26,412.90
	TOTAL - ASSETS	129,920.26	58,739.13



[Handwritten signature]